Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUOCINONIDE

Form:

8 of 8 products shown

4 general benefit · 4 not a benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate (Diprosone): general benefit
  • Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit

8 more in the class list below

Lyderm · DIN 00716863 · 0.05% · Cr

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lyderm · DIN 00716863 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-12-06 · brand LYDERM · ATC D07AC08 FLUOCINONIDE · form Cream · route Topical · ingredients FLUOCINONIDE 0.05 %/W/W · company Soma health products · schedule Prescription
Check this DIN again · Health Canada product record

Lyderm: Formulary list price $0.2550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9276 · Verify on the e-Formulary ↗ (DIN 00716863)

Source record
DIN 00716863: Lyderm Raw flags: sec3=Y Item: 840600017; group id 844; item number 2054; lccId None; manufacturer id TAR Source form: Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.2550; ministry $0.2550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00716863 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9276
Interchangeable products
Lidex · DIN 02161923 · not recorded
Shortage status: resolved shortage (ended 2023-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00716863
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Tiamol · DIN 00598933 · 0.05% · Emol Cr

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tiamol · DIN 00598933 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2004-04-06 · brand TIAMOL CREAM 0.05% · ATC D07AC08 FLUOCINONIDE · form Cream · route Topical · ingredients FLUOCINONIDE 0.05 % · company Westfalia systemat, division of centrico(can) inc. · schedule Prescription
Check this DIN again · Health Canada product record

Tiamol: Formulary list price $0.1980/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1980 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5439 · Verify on the e-Formulary ↗ (DIN 00598933)

Source record
DIN 00598933: Tiamol Raw flags: sec3=Y Item: 840600069; group id 844; item number 2055; lccId None; manufacturer id TAR Source form: Emol Cr; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.1980; ministry $0.1980 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00598933 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5439
Interchangeable products
Lidemol · DIN 02163152 · not recorded
Shortage status: resolved shortage (ended 2022-11-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00598933
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lyderm · DIN 02236997 · 0.05% · Gel

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lyderm · DIN 02236997 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1999-04-15 Health Canada: Marketed since 2023-12-07 · brand LYDERM · ATC D07AC08 FLUOCINONIDE · form Gel · route Topical · ingredients FLUOCINONIDE 0.05 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lyderm: Formulary list price $0.3517/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3517 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60295 · Verify on the e-Formulary ↗ (DIN 02236997)

Source record
DIN 02236997: Lyderm Raw flags: sec3=Y Item: 840600044; group id 844; item number 2056; lccId None; manufacturer id TAR Source form: Gel; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.3517; ministry $0.3517 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236997 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60295
Interchangeable products
Lidex · DIN 02161974 · not recorded
Shortage status: resolved shortage (ended 2020-12-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236997
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lyderm · DIN 02236996 · 0.05% · Oint

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lyderm · DIN 02236996 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2000-04-17 Health Canada: Marketed since 2023-12-07 · brand LYDERM · ATC D07AC08 FLUOCINONIDE · form Ointment · route Topical · ingredients FLUOCINONIDE 0.05 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lyderm: Formulary list price $0.3370/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3370 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60294 · Verify on the e-Formulary ↗ (DIN 02236996)

Source record
DIN 02236996: Lyderm Raw flags: sec3=Y Item: 840600100; group id 844; item number 2057; lccId None; manufacturer id TAR Source form: Oint; strength: 0.05% Recorded listing: General benefit Source prices (unrounded): $0.3370; ministry $0.3370 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60294
Interchangeable products
Lidex · DIN 02161966 · not recorded
Shortage status: resolved shortage (ended 2021-02-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236996
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lidex · DIN 02161923 · 0.05% · Cr

Listed, not a benefitDormant since 2024-07-17 · checked 2026-09-18 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lidex · DIN 02161923 Manufacturer: Valeo Pharma Inc.; listing date 1999-01-20 Health Canada: Dormant since 2024-07-17 · brand LIDEX · ATC D07AC08 FLUOCINONIDE · form Cream · route Topical · ingredients FLUOCINONIDE 0.05 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lidex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20008 · Verify on the e-Formulary ↗ (DIN 02161923)

Source record
DIN 02161923: Lidex Raw flags: notABenefit=Y, sec3=Y Item: 840600017; group id 844; item number 2054; lccId None; manufacturer id VAE Source form: Cr; strength: 0.05% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02161923 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20008
Interchangeable products
Lyderm · DIN 00716863 · $0.2550
Shortage status: discontinued (2023-12-01, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02161923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-17 — choose a marketed DIN from the same-category list.

Lidemol · DIN 02163152 · 0.05% · Emol Cr

Listed, not a benefitDormant since 2024-07-17 · checked 2026-09-02
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lidemol · DIN 02163152 Manufacturer: Valeo Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2024-07-17 · brand LIDEMOL · ATC D07AC08 FLUOCINONIDE · form Cream · route Topical · ingredients FLUOCINONIDE 0.05 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lidemol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19312 · Verify on the e-Formulary ↗ (DIN 02163152)

Source record
DIN 02163152: Lidemol Raw flags: notABenefit=Y, sec3=Y Item: 840600069; group id 844; item number 2055; lccId None; manufacturer id VAE Source form: Emol Cr; strength: 0.05% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163152 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19312
Interchangeable products
Tiamol · DIN 00598933 · $0.1980
Shortage status: resolved shortage (ended 2021-07-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163152
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-17 — choose a marketed DIN from the same-category list.

Lidex · DIN 02161974 · 0.05% · Gel

Listed, not a benefitDormant since 2023-07-27 · checked 2026-09-18
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lidex · DIN 02161974 Manufacturer: Valeo Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2023-07-27 · brand LIDEX · ATC D07AC08 FLUOCINONIDE · form Gel · route Topical · ingredients FLUOCINONIDE 0.05 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lidex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19317 · Verify on the e-Formulary ↗ (DIN 02161974)

Source record
DIN 02161974: Lidex Raw flags: notABenefit=Y, sec3=Y Item: 840600044; group id 844; item number 2056; lccId None; manufacturer id VAE Source form: Gel; strength: 0.05% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02161974 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19317
Interchangeable products
Lyderm · DIN 02236997 · $0.3517
Shortage status: resolved shortage (ended 2021-07-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02161974
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-07-27 — choose a marketed DIN from the same-category list.

Lidex · DIN 02161966 · 0.05% · Oint

Listed, not a benefitDormant since 2023-07-27 · checked 2026-09-18
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lidex · DIN 02161966 Manufacturer: Valeo Pharma Inc.; listing date 1996-10-01 Health Canada: Dormant since 2023-07-27 · brand LIDEX · ATC D07AC08 FLUOCINONIDE · form Ointment · route Topical · ingredients FLUOCINONIDE 0.05 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Lidex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19203 · Verify on the e-Formulary ↗ (DIN 02161966)

Source record
DIN 02161966: Lidex Raw flags: notABenefit=Y, sec3=Y Item: 840600100; group id 844; item number 2057; lccId None; manufacturer id VAE Source form: Oint; strength: 0.05% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02161966 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19203
Interchangeable products
Lyderm · DIN 02236996 · $0.3370
Shortage status: resolved shortage (ended 2021-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02161966
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2023-07-27 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

MOMETASONE FUROATE

· 6 products · General benefit · strengths: 0.1% · Cr, Lot, Oint

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For topical use in the management of acute or chronic dermatoses responsive to corticosteroids. https://pdf.hres.ca/dpd_pm/00001696.PDF PM date: not printed or not captured Source product: TIAMOL CREAM 0.05%; DIN 00598933; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Lidex · DIN 02161923 Shortage status: discontinued (2023-12-01, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02161923

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Lidex, Lidemol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026